William K Heiden
CIK 1214939 · President & CEO · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMAG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1100 WINTER STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATRA | Director | 34,188 | $8.35 | $285.5K | $25.3K | 14 | 2026-06-11 |
| MGNX | Director | 114,750 | $2.19 | $251.3K | $150.5K | 7 | 2026-05-20 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President & CEO | 424,612 | — | — | -$7.16M | 30 | 2020-03-04 |
| GTC BIOTHERAPEUTICS INC (GTCB) Delisted | Director | — | — | — | $0 | 1 | 2009-10-05 |
Recent Filings · Page 4 of 6
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-05-17 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Tax (F) | +11,812 | $215.8K | EDGAR |
| 2016-03-01 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Mixed | +17,737 | -$492.0K | EDGAR |
| 2016-01-05 | ATRA | Grant (A) | — | $0 | EDGAR |
| 2015-11-25 | ATRA | Grant (A) | — | $0 | EDGAR |
| 2015-10-02 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Sell (S) | −2,000 | -$79.4K | EDGAR |
| 2015-09-02 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Sell (S) | −2,000 | -$122.4K | EDGAR |
| 2015-08-05 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Sell (S) | −2,000 | -$129.1K | EDGAR |
| 2015-07-17 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Mixed | — | -$1.24M | EDGAR |
| 2015-07-02 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Sell (S) | −2,000 | -$138.8K | EDGAR |
| 2015-06-08 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Mixed | −6,875 | -$3.90M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.